Trials / Recruiting
RecruitingNCT04868604
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 54 (estimated)
- Sponsor
- Clarity Pharmaceuticals Ltd · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 64Cu-SAR-bisPSMA | 64Cu-SAR-bisPSMA |
| DRUG | 67Cu-SAR-bisPSMA | 67Cu-SAR-bisPSMA |
Timeline
- Start date
- 2021-08-11
- Primary completion
- 2026-09-01
- Completion
- 2026-09-01
- First posted
- 2021-05-03
- Last updated
- 2026-02-05
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04868604. Inclusion in this directory is not an endorsement.